| First Author | Ma X | Year | 2024 |
| Journal | Adv Sci (Weinh) | Volume | 11 |
| Issue | 31 | Pages | e2400726 |
| PubMed ID | 38881534 | Mgi Jnum | J:373299 |
| Mgi Id | MGI:8251013 | Doi | 10.1002/advs.202400726 |
| Citation | Ma X, et al. (2024) Targeting Nr2e3 to Modulate Tet2 Expression: Therapeutic Potential for Depression Treatment. Adv Sci (Weinh) 11(31):e2400726 |
| abstractText | Epigenetic mechanisms such as DNA methylation and hydroxymethylation play a significant role in depression. This research has shown that Ten-eleven translocation 2 (Tet2) deficiency prompts depression-like behaviors, but Tet2's transcriptional regulation remains unclear. In the study, bioinformatics is used to identify nuclear receptor subfamily 2 group E member 3 (Nr2e3) as a potential Tet2 regulator. Nr2e3 is found to enhance Tet2's transcriptional activity by binding to its promoter region. Nr2e3 knockdown in mouse hippocampus leads to reduced Tet2 expression, depression-like behaviors, decreased hydroxymethylation of synaptic genes, and downregulation of synaptic proteins like postsynaptic density 95 KDa (PSD95) and N-methy-d-aspartate receptor 1 (NMDAR1). Fewer dendritic spines are also observed. Nr2e3 thus appears to play an antidepressant role under stress. In search of potential treatments, small molecule compounds to increase Nr2e3 expression are screened. Azacyclonal (AZA) is found to enhance the Nr2e3/Tet2 pathway and exhibited antidepressant effects in stressed mice, increasing PSD95 and NMDAR1 expression and dendritic spine density. This study illuminates Tet2's upstream regulatory mechanism, providing a new target for identifying early depression biomarkers and developing treatments. |
